Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Serina Therapeutics, Inc.AGE · Entity 9581 | Director | June 21, 2021 | June 24, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Serina Therapeutics, Inc.
Report date June 21, 2021 · Filed June 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2031-06-20 | Direct | 65,000 |
Reported balance
After 2021-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-21 · Grant · Acquired 65,000 · Balance 65,000 F1: Options will vest and become exercisable in four equal quarterly installments on June 30, 2021, September 30, 2021, December 31, 2021, and March 31, 2022, provided that the grantee remains a director on the last day of the applicable calendar quarter. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2031-06-20 | Direct | 35,000 |
Reported balance
After 2021-06-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-21 · Grant · Acquired 35,000 · Balance 35,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Options will vest and become exercisable in four equal quarterly installments on June 30, 2021, September 30, 2021, December 31, 2021, and March 31, 2022, provided that the grantee remains a director on the last day of the applicable calendar quarter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2021 Filed Jun 24, 2021 01:46 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantOption to Purchase Common Stock · Derivative | 35,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001209191-21-042894 · doc4.xml · derivative · entry 2 MAY MICHAEL H · CIK 0001785908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-06-20 Read SEC document |
| June 21, 2021 Filed Jun 24, 2021 01:46 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantOption to Purchase Common Stock · Derivative | 65,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001209191-21-042894 · doc4.xml · derivative · entry 1 MAY MICHAEL H · CIK 0001785908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-06-20 F1 · derivative.exercise_date: Options will vest and become exercisable in four equal quarterly installments on June 30, 2021, September 30, 2021, December 31, 2021, and March 31, 2022, provided that the grantee remains a director on the last day of the applicable calendar quarter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.